Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development

1 year ago

LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development…

Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval

1 year ago

UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support…

Neuroscience Center in Sweden Orders Nexstim NBS 5 System

1 year ago

Press release, Helsinki, 13 September 2023 at 10 AM (EEST) Neuroscience Center in Sweden Orders Nexstim NBS 5 System Nexstim…

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

1 year ago

The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on…

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

1 year ago

Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration VenturesSeptember 13, 2023: Glasgow, Scotland – Mironid,…

Novo Nordisk conducts a two-for-one stock split

1 year ago

Bagsværd, Denmark, 13 September 2023 – As communicated on 10 August 2023 in connection with the release of Novo Nordisk's…

DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round

1 year ago

MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round…

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

1 year ago

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the…

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

1 year ago

Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber…